Interesting note from Pfizer after they decided to
Post# of 72440
(Total Views: 281)
Posted On: 01/13/2018 7:16:37 AM
Interesting note from Pfizer after they decided to stop R&D into alzheimers drugs...
This decision was driven by science; not cost. As the fourth largest investor in pharmaceutical research and development worldwide, we expect limited impact, if any, to our overall investment in R&D as a result of this decision. Our reallocation of funding will allow us to place greater focus on areas where we believe we have the strongest possibility of bringing important therapies and vaccines to patients in the near term. This includes promising therapies in other areas where there is a strong unmet patient need, including potential new breakthrough treatments for cancer, vaccine candidates for devastating infections such as Clostridium difficile and Staphylococcus aureus, new approaches to chronic inflammatory diseases, potential therapies for debilitating diseases such as Duchenne muscular dystrophy, potential non-opioid pain treatments for chronic pain conditions and potential medicines to combat the growing epidemic in NASH or fatty liver disease.
Interesting to hear a BP bring up chronic inflammatory diseases as a focus of R&D funding....
This decision was driven by science; not cost. As the fourth largest investor in pharmaceutical research and development worldwide, we expect limited impact, if any, to our overall investment in R&D as a result of this decision. Our reallocation of funding will allow us to place greater focus on areas where we believe we have the strongest possibility of bringing important therapies and vaccines to patients in the near term. This includes promising therapies in other areas where there is a strong unmet patient need, including potential new breakthrough treatments for cancer, vaccine candidates for devastating infections such as Clostridium difficile and Staphylococcus aureus, new approaches to chronic inflammatory diseases, potential therapies for debilitating diseases such as Duchenne muscular dystrophy, potential non-opioid pain treatments for chronic pain conditions and potential medicines to combat the growing epidemic in NASH or fatty liver disease.
Interesting to hear a BP bring up chronic inflammatory diseases as a focus of R&D funding....
(8)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼